micrornas signatures, bioinformatics analysis of mirnas, mirna mimics and antagonists, and mirna therapeutics in osteosarcoma
Clicks: 576
ID: 135729
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
84.0
/100
576 views
416 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #1 of 7 articles by views in management and economics review
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract MicroRNAs (miRNAs) involved in key signaling pathways and aggressive phenotypes of osteosarcoma (OS) was discussed, including PI3K/AKT/MTOR, MTOR AND RAF-1 signaling, tumor suppressor P53- linked miRNAs, NOTCH- related miRNAs, miRNA -15/16 cluster, apoptosis related miRNAs, invasion-metastasis-related miRNAs, and 14Q32-associated miRNAs cluster. Herrin, we discussed insights into the targeted therapies including miRNAs (i.e., tumor-suppressive miRNAs and oncomiRNAs). Using bioinformatics tools, the interaction network of all OS-associated miRNAs and their targets was also depicted.
| Reference Key |
otoukesh2020cancermicrornas
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Babak Otoukesh;Mehdi Abbasi;Habib-o-Lah Gorgani;Hossein Farahini;Mehdi Moghtadaei;Bahram Boddouhi;Peyman Kaghazian;Shayan Hosseinzadeh;Atefe Alaee |
| Journal | management and economics review |
| Year | 2020 |
| DOI |
10.1186/s12935-020-01342-4
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.